

cyclomedica technegas cyclopet ultralute

30 May 2025

The Manager Company Announcements Office Australian Securities Exchange Limited 20 Bridge Street Sydney NSW 2000

Cyclopharm Ltd ABN 74 116 931 250 Unit 4, 1 The Crescent Kingsgrove NSW 2208 Australia T 61 2 9541 0411 F 61 2 9543 0960 www.cyclopharm.com.au

Results of Annual General Meeting on 30 May 2025

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise that all resolutions put forth to the shareholders were duly passed.

Details of the resolutions and the proxies received in respect of each resolution are set out in the attached voting results summary.

Janes & MCBreyer

James McBrayer Managing Director and Company Secretary

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer Managing Director, CEO and Company Secretary Cyclopharm Limited T: +61 (02) 9541 0411 M:+61 (0) 0418 967 073

Disclosure of Proxy Votes

Cyclopharm Limited Cyclopharm Limited - 2025 Annual General Meeting Friday, 30 May 2025



In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

| | | | Proxy Votes | | | Poll Results (if applicable) | | | Results | |
|--|---|--|----------------------|--------------------|-----------|------------------------------|----------------------|--------------------|-----------|---------|
| Resolution | Decided by Show of Hands (S) or Poll (P) | Total Number of Proxy Votes exercisable by proxies validly appointed | FOR | AGAINST | ABSTAIN | PROXY'S DISCRETION | FOR | AGAINST | ABSTAIN | OUTCOME |
| 1 Remuneration Report | Ρ | 59,515,880 | 59,178,529 99.43% | 283,084 0.48% | 4,182 | 54,267 0.09% | 60,060,708 99.53% | 283,084 0.47% | 31,398 | - |
| 2 Re-election of Director | Ρ | 62,559,799 | 62,476,956 99.87% | 27,700 0.04% | 12,500 | 55,143 0.09% | 63,464,706 99.96% | 27,700 0.04% | 12,500 | Carried |
| 3 Approval of grant of performance rights | Ρ | 59,825,529 | 59,314,524 99.15% | 460,862 0.77% | 2,746,770 | 50,143 0.08% | 60,292,381 99.24% | 460,862 0.76% | 2,773,986 | Carried |
| 4 Approval of grant of performance rights to the Managing Director for FY25 STI | Ρ | 59,976,637 | 59,465,632 99.15% | 461,556 0.77% | 2,595,662 | 49,449 0.08% | 60,442,795 99.24% | 461,556 0.76% | 2,622,878 | Carried |
| 5 Approval of grant of performance rights to the Managing Director for FY25 LTI | Ρ | 59,976,637 | 54,564,667 90.98% | 5,362,703 8.94% | 2,595,662 | 49,267 0.08% | 55,541,648 91.19% | 5,362,703 8.81% | 2,622,878 | Carried |
| 6 Approval of Non-executive director remuneration | Ρ | 62,231,832 | 62,104,206 99.79% | 73,177 0.12% | 340,000 | 54,449 0.09% | 63,013,783 99.88% | 73,177 0.12% | 407,479 | Carried |
| 7 Approval of prior issue of Placement Shares | Ρ | 62,572,299 | 62,456,748 99.82% | 81,960 0.13% | 0 | 33,591 0.05% | 63,445,269 99.87% | 81,960 0.13% | 0 | Carried |

